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Abstract
Axonal dystrophies (AxDs) are swollen and tortuous neuronal processes that are associated with extracellular depositions
of amyloid β (Aβ) and have been observed to contribute to synaptic alterations occurring in Alzheimer’s disease.
Understanding the temporal course of this axonal pathology is of high relevance to comprehend the progression of the
disease over time. We performed a long-term in vivo study (up to 210 days of two-photon imaging) with two transgenic
mouse models (dE9xGFP-M and APP-PS1xGFP-M). Interestingly, AxDs were formed only in a quarter of GFP-expressing
axons near Aβ-plaques, which indicates a selective vulnerability. AxDs, especially those reaching larger sizes, had long
lifetimes and appeared as highly plastic structures with large variations in size and shape and axonal sprouting over time.
In the case of the APP-PS1 mouse only, the formation of new long axonal segments in dystrophic axons (re-growth
phenomenon) was observed. Moreover, new AxDs could appear at the same point of the axon where a previous AxD
had been located before disappearance (re-formation phenomenon). In addition, we observed that most AxDs were
formed and developed during the imaging period, and numerous AxDs had already disappeared by the end of this time.
This work is the first in vivo study analyzing quantitatively the high plasticity of the axonal pathology around Aβ plaques.
We hypothesized that a therapeutically early prevention of Aβ plaque formation or their growth might halt disease
progression and promote functional axon regeneration and the recovery of neural circuits.
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Introduction
Alzheimer’s disease (AD) is typically associated with a
set of neuronal cytoskeletal alterations – the formation
of neurofibrillary tangles (NFTs), neuropil threads and
dystrophic neurites, which are associated with dendritic
spine and synapse loss, as well as neuronal degeneration
(e.g., [2, 42, 53, 61]). These pathological changes develop
in a characteristic spatiotemporal progression across the
cerebral cortex and other brain regions in AD patients
[12] and AD mouse models [10]. Dystrophic neurites are
swollen and tortuous neurites, which were originally de-
tected by Alois Alzheimer because of their argyrophilia [1].
They have a variable morphology and composition depend-
ing on the pathological stage of AD [44, 51, 58, 60, 62].
They are closely associated with extracellular deposits of
amyloid β (Aβ), known as “Aβ plaques”, which represent
another hallmark of AD pathology. Dystrophic neurites are
normally formed in axons [18, 24, 25, 36, 38, 57, 58, 62].
From now on we will refer to axonal dystrophies as AxDs.
Synaptic loss is the major neurobiological basis of
cognitive dysfunction in AD. Synaptic failure is an early
event in the pathogenesis that is already clearly detect-
able in patients with mild cognitive impairment (MCI), a
prodromal state of AD. Compelling evidence suggests
that different forms of Aβ peptide and abnormal phos-
phorylated tau induce synaptic loss in AD and transgenic
mice models [6]. Synaptic breakdown in AD mouse
models with no relation to amyloid plaques but as a conse-
quence of high level of soluble amyloid beta has been re-
ported [3, 4]. Aβ plaques are associated to alterations of
dendrites and axons that are in contact or in the proximity
to them, and with a clear decrease of synapses. The major-
ity of studies has been focused on alterations of dendrites
in contact with Aβ plaques [8, 9, 28, 32–35, 43, 52, 53, 59].
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However, less attention has been paid to the alterations of
axons [2]. This is unfortunate since the loss of synapses
found in or around Aβ plaques could be related to alter-
ations of postsynaptic targets (dendrites), presynaptic
elements (axons) or both.
For this reason, we consider that understanding the
temporal course of the axonal pathology is of high rele-
vance to comprehend the progression of the disease over
time and define possible therapeutic targets and the
window time where a treatment might be effective. The
dystrophic pathology is one of the alterations of the dis-
ease that has been better resembled in the animal
models [2, 13, 53, 59]. Previous in vivo studies have been
undertaken to analyze the dystrophic pathology over
time [13, 15, 23, 53, 59]. One of the main findings from
these studies was that the elimination rates were signifi-
cantly higher than the formation rates, suggesting that
there is a gradual net loss of neuronal structures over
time near Aβ plaques, causing a permanent disruption
of neuronal connections [59]. Furthermore, it has been
reported that the dystrophic pathology is reversible with
an anti-Aβ antibody treatment [13] and curcumin [23].
However, these studies did not perform either a detailed
quantitative analysis of the observed changes or a long-
term study of the dystrophic pathology (the longest was
only 35 days). Moreover, the relationship of specific
axonal dystrophic changes to Aβ accumulation has not
been addressed. In the present work, we performed a
detailed long-term study (of up to 210 days and weekly
imaging) focusing on the formation, development and
elimination of AxDs with the aim of examining the
plasticity of AxDs and their potential to be reversed. To
achieve these objectives, we have used two-photon in
vivo imaging and electron microscopy including trans-
mission electron microscopy (TEM) and focused ion
beam/scanning electron microscopy (FIB/SEM).
Materials and methods
Animals and housing
Mouse lines Amyloid Precursor Protein – Preseniline 1
(APP-PS1) (dE9) [30], APP-PS1 [48] and the Green
Fluorescent Protein-M (GFP-M) [19] were used in this
study. The dE9 and GFP-M lines were purchased from
The Jackson Laboratory (Bar Harbor, USA). The APP-
PS1 mice were provided by Matthias Jucker (University
of Tübingen and German Center for Neurodegenerative
Diseases, Tübingen, Germany). Heterozygous dE9 and
APP-PS1 mice were crossed with heterozygous GFP-M
mice resulting in triple transgenic dE9xGFP-M and
APP-PS1xGFP-M mice, which were inbred. Heterozy-
gous triple transgenic mice of mixed gender were used
for experiments at the ages indicated below. Mice were
group-housed under pathogen-free conditions until sur-
gery, after which they were singly housed in standard
cages with food and water ad libitum. The studies were
carried out in accordance with an animal protocol ap-
proved by the Ludwig-Maximilians-University Munich
and the government of Upper Bavaria (Az. 55.2-1-54-
2531-188-09).
Two-photon in vivo imaging
For in vivo imaging, a chronic cranial window was
prepared as described previously [22]. Surgery was per-
formed in six 6-month-old dE9xGFP-M and seven 2-
month-old APP-PS1xGFP-M mice. In vivo imaging
began after a 4–5-week post-surgery recovery period,
using an LSM 7 MP setup (Zeiss) equipped with a
MaiTai laser (Spectra Physics). Around 24 h before im-
aging, Methoxy-X04 (0.4 to 2.4 mg/Kg body weight,
Xcessbio, San Diego, CA, USA) was intraperitoneally
injected to visualize Aβ plaques in vivo [31]. Imaging
was performed once a week for 24 weeks in dE9xGFP-M
mice and for 30 weeks in the APP-PS1xGFP-M mice. In
the dE9 model, the imaging began when the mice were
around 7 months-old (the age corresponding to the ini-
tial stage of the amyloid pathology) and was prolonged
until they were approximately 13 months-old (corre-
sponding to the advanced stage of the disease). In the
APP-PS1 mouse, the imaging began when the mice were
around 3 months-old (the age corresponding to the ini-
tial stage of the amyloid pathology) and was prolonged
until they were approximately 10 months-old (which
corresponds to the advanced stage of the disease).
Two-photon excitation of Methoxy-X04-labeled Aβ
plaques was performed at 750 nm and the signal was
detected using a short pass (SP) 485 nm filter. Two-
photon excitation of GFP-expressing neuronal structures
was performed at 880 nm and the signal was detected
using a bandpass (BP) 500–550 nm filter. To exclude
false positive fluorescent spots from the analysis, we also
recorded emissions at 590–650 nm. These auto-
fluorescent spots were found both in the neuropil and
within neuronal and glial cells (Additional file 1). A × 20
1.0 NA water-immersion objective (Zeiss) was used.
Stereological coordinates were used to locate the som-
atosensory cortex [29]. Overview images were taken at
low resolution (logical size 512 × 512 pixels; physical size
x, y, z: 424.3 × 424.3 × 300 μm; z-step = 3 μm) to a depth
of 300 μm (supragranular layers) to find the same pos-
ition over time. At least 2–3 overviews were taken per
animal at each imaging session. Note that performing
long-term in vivo two-photon imaging weekly during
near 6 months is challenging. Although more imaging
positions were acquired only those that were successfully
imaged during the whole time period were used for the
quantitative analysis. These numbers are shown in
Additional file 2. Two types of images were taken to
perform the analysis:
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i) The three-dimensional (3D) reconstruction of AxDs
over time: High magnification images (logical size
512 × 512 pixels; physical size x, y, z: 84.9 × 84.9 ×
40–60 μm; z-step = 1 μm) of single Aβ plaques
stained with Methoxy-X04 and the GFP-expressing
neurites around them (46 GFP-expressing axons
around 6 Aβ plaques in the dE9xGFP-M mouse
model (n = 6), 10 of which became dystrophic and
were 3D reconstructed; 58 GFP-expressing axons
around 6 Aβ plaques were followed in the APP-
PS1xGFP-M mouse model (n = 7), 16 of which
became dystrophic and were 3D reconstructed).
Care was taken to ensure similar fluorescence levels
in space and time.
ii) The spatiotemporal relationship between Aβ plaques
and AxDs: Panoramic high resolution images (logical
size 1400 × 1400 pixels; physical size x, y, z: 202.3 ×
202.3 × 39.9–50.1 μm; z-step = 0.3 μm) showing
several Aβ plaques stained with Methoxy-X04 and
GFP-expressing neurites near and far from them (33
Aβ plaques and 52 AxDs were followed over time in
the APP-PS1xGFP-M mouse model (n = 7)). AxDs
were not 3D reconstructed at all time points, but
rather only on those days when the volume of the
AxD was visually observed to be largest. Thus, we
recorded “the maximum volume data” over time.
Moreover, the day of appearance and disappearance
and the type of axon in which the AxD appeared
was also annotated for every single AxD. Care was
taken to ensure similar fluorescence levels in space
and time.
Electron microscopy preparation and TEM and FIB/SEM
imaging
A correlative two-photon in vivo imaging and TEM or
FIB/SEM microscopy method was used to analyze the
ultrastructure of the same Aβ plaques (and AxDs around
them) as those previously studied in vivo [11]. Briefly,
after the final in vivo imaging session, three dE9xGFP-M
mice were transcardially perfused with 2% paraformalde-
hyde and 2.5% glutaraldehyde in 0.12 M PB, pH 7.4.
Later, regions of interest in a thick section cut from the
window region were marked by laser, using the two-
photon-laser system according to the Near Infrared
Branding (NIRB) technique [7]. This thick section was
resectioned in thinner sections of 50 μm with a LeicaVibra-
tome (VT1200, Leica Microsystems, Wetzlar, Germany).
After the cutting, sections were analyzed again under the
two-photon microscope to find those slices where the
marked regions of interest were present. Selected 50 μm
sections containing the regions of interest were post-
fixed in 2.5% glutaraldehyde/2% paraformaldehyde in
0.1 M cacodylate buffer for 1 h, treated with 1% osmium
tetroxide in 0.1M cacodylate buffer for 1 h, dehydrated,
and flat embedded in Araldite resin [17, 41]. The postfixa-
tion, dehydration and embedding steps were done with a
laboratory microwave oven with a vacuum chamber and
cooling stage (Ted Pella, Redding, CA, USA).
In those samples that were analyzed by TEM, plastic-
embedded sections were studied by correlative light and
electron microscopy, as described in detail elsewhere
[17]. Briefly, sections were photographed under the light
microscope and then serially cut into semithin (2-μm
thick) sections on a Leica ultramicrotome (EM UC6,
Leica Microsystems). The semithin sections were stained
with 1% toluidine blue in 1% borax, examined under the
light microscope, and then photographed to locate the
NIRB-marked region of interest. Serial ultrathin sections
(50- to 70-nm thick) were obtained from selected semi-
thin sections on a Leica ultramicrotome, and collected
on formvar-coated single-slot nickel grids and stained
with uranyl acetate and lead citrate. Digital images were
captured at different magnifications on a Jeol JEM-1011
TEM (JEOL Inc., MA, USA) equipped with an 11 Mega-
pixel Gatan Orius CCD digital camera.
In those samples that were analyzed by FIB/SEM, semi-
thin sections (1-μm thick) were obtained by means of a
Leica ultramicrotome from the surface of the block until
the most superficial NIRB marks around the region of
interest were reached (Additional file 3). The blocks
containing the embedded tissue were then glued onto
aluminum sample stubs using conductive carbon adhesive
tabs (Electron Microscopy Sciences, Hatfield, PA). All sur-
faces of the Araldite blocks, except for the top surface
containing the sample, were covered with colloidal silver
paint (Electron Microscopy Sciences, Hatfield, PA) to pre-
vent charging artifacts. The stubs with the mounted
blocks were then placed into a sputter coater (Emitech
K575X, Quorum Emitech, Ashford, Kent, UK) and were
coated with platinum for 10 s to facilitate charge dissipa-
tion. The marks were still visible on the surface of the
block with the FIB/SEM. The ultrastructural 3D study of
these samples was carried out using a combined FIB/SEM
microscope (Neon40 EsB, Carl Zeiss NTS GmbH,
Oberkochen, Germany). The sequential automated use of
alternating FIB milling and SEM imaging allowed us to
obtain long series of images representing 3D sample vol-
umes of selected regions. Images of 2048 × 1536 pixels at
a resolution of 6.203 nm per pixel were taken; each indi-
vidual photomicrograph therefore covered a field of view
of 12.7 × 9.5 μm. The layer of material milled by the FIB
in each cycle (equivalent to section thickness) was 30 nm.
A total of 305 serial sections were obtained. Thus, the
physical size of the stack was (x, y, z) 12.7 × 9.5 × 9.15 μm.
Images, data processing and statistics
The deconvoluted two-photon images (AutoQuantX2,
Media Cybernetics) were processed later by means of
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Imaris software (Bitplane AG, Zurich, Switzerland) to
obtain the 3D reconstructions of the dystrophic axons
and the Aβ plaques, as well as the volumes of each of
them at the different time points. For the alignment
(registration) of the stack of FIB/SEM images, we used
Fiji (http://fiji.sc). Reconstruct Software v1.1.0.0 [21] was
used to carry out the 3D reconstruction of the AxDs and
the microglial cell.
Regarding Aβ plaques: the images were analyzed as
time series of 3D images in Imaris. First, images were
contrast-normalized (i.e., based on the average and
standard deviation of the 3D stack intensities). Plaque
volumes were extracted by 3D-surface-rendering with
background subtraction and a threshold of 500. Newly
formed Aβ plaques were tracked back to the first time
point when they appeared and were only assessed when
present for at least 3 time points. Regarding AxDs: they
were manually segmented in the images stacks. Only
those AxDs and parent axons that were present in the
whole imaging stack at all time points were recon-
structed. An axonal segment was considered dystrophic
when its volume was double that of the non-dystrophic
axonal segment. When possible, non-dystrophic axonal
volume was calculated as the average of three measure-
ments at three different time points for the same axonal
segment that would later go on to show the AxD. When
the AxD was already present from the first day of obser-
vation, non-dystrophic segments of the same axon out-
side the Aβ plaque were averaged at three different time
points. In all cases, reference non-dystrophic axonal
segments had the same length as the maximal segment
affected by the AxD (Additional file 4).
Photoshop CS6 (Adobe Systems Inc., San José, CA,
USA) software was used to generate the figures.
All data sets were tested for normality with the
Kolmogorov-Smirnov and D’Agostino and Pearson omni-
bus normality tests with a significance level set to p = 0.05,
before the appropriate parametric or non-parametric stat-
istical comparison test was carried out with GraphPad
Prism 5.04 (GraphPad Inc., La Jolla, CA, USA).
Results
Kinetics of formation, development and elimination of
AxDs: 3D reconstructions
In the dE9 mouse, we observed a total of 46 axonal seg-
ments located not further than 40 μm from the border
of the adjacent Methoxy-X04-stained amyloid plaques.
Out of all of these axonal segments, we detected the for-
mation of AxDs in only 22% of them (n = 10 AxDs; all
were reconstructed with Imaris software) (Figs. 1, 2 and
3). In the APP-PS1 mouse, we examined a total of 58
axonal segments located not further than 40 μm from
the border of the adjacent Methoxy-X04-stained amyloid
plaques. Out of all these axonal segments, we only
detected the formation of AxDs in 28% of them (n = 16
AxDs, all were reconstructed with Imaris software)
(Figs. 1 and 3). We observed that a given AxD presented
size variations over time (intra-size variations) and
distinct AxDs could have very different sizes (inter-size
variations) (Figs. 1 and 2). Due to this heterogeneity, we
performed a detailed quantitative study of the morpho-
logical changes that take place and the kinetics of forma-
tion, development and elimination of single AxDs over
time. Each AxD was independently named and they are
referred to in the text and graphs as “dys 1–10” in the
dE9 mouse and “dys 1–16” in the APP-PS1 mouse.
Axons of control mice (GFP-M) displayed unchanged
morphology after long-term in vivo two-photon imaging
(observations are not shown).
Using Imaris software, 3D reconstructions of the AxDs
were performed and it was possible to quantify their
volume and study their morphological changes over time
(Figs. 1 and 2).
Morphological changes of AxDs: size and shape
AxDs were highly variable in terms of their size both in
the dE9 and the APP-PS1 models. AxDs sizes varied
between 45 and 3081 μm3 in the dE9 model and be-
tween 25 and 2814 μm3 in the APP-PS1 model (Fig. 3).
Moreover, AxDs did not grow continuously; indeed their
volume grew and decreased over time. Changes in vol-
ume were more prominent in the larger AxDs than in
the smaller ones. For example, dys 3 in the dE9 model
ranged between 159 and 3081 μm3 (Figs. 3a and 4e–g),
while smaller AxDs showed less pronounced changes
(e.g., dys 5 in the dE9 model only changed between 45
and 76 μm3; Fig. 3a). Thus, it can be observed that larger
AxDs at some point are similar in size to those AxDs
that are smaller over their whole lifetime.
When we calculated the ratio between the volume of
an AxD and the volume of the non-dystrophic axonal
segment of the same AxD (size ratio) (Fig. 3c, d;
Additional file 4), we observed that the volume increase
of the AxDs ranged between 2 and 39 times in the dE9
model and between 2 and 35 times in the APP-PS1
model (Table 1).
In some cases, both in the dE9 and the APP-PS1 mice,
we observed significant changes in the shape of the
AxDs and the formation of more than one swollen vari-
cosity of irregular shape with new short axonal segments
leaving from the dystrophic structures (axonal sprouting)
(Fig. 2). This phenomenon was observed in those AxDs
reaching larger sizes (greater than 500 μm3) —n = 3 in the
dE9 and n = 7 in the APP-PS1 mice, see Table 1 and
Fig. 3— but was not seen in the smaller ones that nor-
mally remained as single spherical swollen varicosities
(Fig. 1a-c). To quantify this observation, we estimated the
mean sphericity factor of each AxD over time. The
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sphericity factor, defined as the ratio of the surface area of
a sphere to the surface area of the structure analyzed
(both with the same volume) provides a quantitative
record of the morphological complexity of the 3D-
reconstructed AxDs, since spherical objects would yield a
sphericity value close to 1, while more complex shapes
Fig. 1 Intra- and inter-size variations of AxDs over time. (a-c), Maximum projection (40 optical sections, z-step = 1 μm) of a stack of images taken
with a two-photon microscope in the somatosensory cortex of a dE9 mouse at three different time points. Small AxDs (yellow and red arrows, dys 6
and 7, respectively) in GFP-expressing axons (green) are present around an Aβ plaque stained with Methoxy-X04 (blue). (d-i), Maximum projection (32
optical sections, z-step = 1 μm) of a stack of images taken with the two-photon microscope in the somatosensory cortex of the APP-PS1 mouse at six
different time points. A large AxD (brackets in e-h; dys 4) in a GFP-expressing axon (green; arrowheads) is present around an Aβ plaque stained with
Methoxy-X04 (blue). This plaque was observed growing in size from its birth (d) to maturation (i). There is a degeneration of the distal part of the axon
and the AxD remains at the edge of the proximal part of the axon (h). On the final day of imaging, the whole axon had disappeared (i). AxDs in panels
a-c do not show strong variations in size and shape over time as compared to the AxD in panels d-i, and numerous axons and dendritic processes do
not become dystrophic. There is an axon segment that does not become dystrophic and disappears (white arrow). (j-m), 3D reconstructions of the
AxD showed in images e-h, respectively, using Imaris software. The dystrophic segment of the axon is shown in red and this is the portion of the axon
that was used to calculate the AxD volume (Fig. 3b). The days shown refer to the number of days after day 0 (when imaging began). Purple arrows in
g-i point out a re-growing axon that is also shown in greater detail in Fig. 5. Scale bar (in m): 19.5 μm in a-m
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with larger surface-to-volume ratios would yield progres-
sively lower values. We found an inverse correlation
(Pearson’s r: −0.7366, p < 0.0001; Fig. 3e) between the
sphericity and the maximum volume that the AxD
reaches, so larger AxDs showed smaller sphericity factors
and vice versa. Thus, larger AxDs tend to be complex,
non-spherical shapes.
Axonal sprouting: re-growth phenomenon
In the case of the APP-PS1 mouse only, the formation
of new long axonal segments in dystrophic axons (re-
growth phenomenon, n = 3 (out of 17)) was observed
(Fig. 5 and Additional file 5). These new axonal
segments were observed either (i) leaving from a dys-
trophic structure (n = 1 (dys 13)) with a maximum
Fig. 2 Three-dimensional reconstructions of AxDs. (a-f), Images obtained (over 148 days) of the same dystrophic axon expressing GFP (dys 1) in
contact with an Aβ plaque stained with Methoxy-X04 (blue) in the supragranular layers of the somatosensory cortex of a dE9 mouse (two-photon
microscopy). (g-l), Three-dimensional reconstructions of the AxD showed in panels a-f, respectively, using Imaris software. On day 91 (j) the
degeneration of the distal part of the axon (arrowheads) begins. This degenerative process is completed in the successive days but the AxD
remains at the end of the cut axon (k, l). Note that the AxD presents numerous changes in volume and shape. The existence of more than one
swollen varicosity (asterisks in e show an example) and short axonal sprouting can be identified (arrows in b, c, f, h, i and l). Note that the
dystrophic segment of the axon is shown in red and from this part the numerical AxD volume was calculated and plotted in Fig. 3a. The days
shown refer to the number of days after day 0 (when imaging began). Scale bar (in l): 19.5 μm in a-l
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Fig. 3 (See legend on next page.)
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observed length of the new axonal segment of 53 μm or
(ii) re-growing from axons that were previously sec-
tioned at a dystrophic point (n = 2) with a maximum
observed length of the new axonal segments of 104.5
(dys 9, Fig. 5) and 32 μm (this AxD was not 3D recon-
structed, but is shown in Additional file 5). The re-
grown segment followed a different trajectory from the
previously existing axon segment (Fig. 5 and Additional
file 5, Table 1).
Lifetime and elimination of AxDs
We found that on average AxDs had a very long life-
time. It was common to find AxDs that were present
for more than 100 days both in the dE9 and the
APP-PS1 mice —n = 7 (out of 10) and n = 7 (out of
16), respectively— (see Table 1). In the APP-PS1
mouse, it was feasible to analyze a larger number of
AxDs (see next section and Additional file 6). In this
case, the average lifetime of AxDs was 76.43 ± 7.8 days
(See figure on previous page.)
Fig. 3 Volume and morphological changes of in vivo AxDs over time. (a, b), Graphs showing the changes in volume of the different AxDs
studied over time in the dE9 (a) and the APP-PS1 (b) mice. (c, d), Size ratio indicates the ratio between the volume of an AxD and the volume of
its equivalent non-dystrophic axonal segment. Graphs correspond to the same AxDs represented in a, b, respectively. With the aim of simplifying
the graph visualization, the AxD size ratio was plotted only from the imaging day in which the AxD became dystrophic (size ratio ≥2, dashed line).
Note that in a-d the scale has been transformed to Log 10 to illustrate that volume values of larger and smaller AxDs can be very similar at some
time points. The days shown refer to the number of days after day 0 (when imaging began). Graph legend: Asterisks refer to those AxDs that
disappear at the end of the imaging period (one asterisk means the parental axon stays and two asterisks mean that the AxD disappears due to
the loss of the parental axon); underlined AxDs (dys) are those that show morphology changes (more than one swollen varicosity of irregular
shape and new short axonal segments). (e), Correlation between the mean sphericity value over time and the maximum volume that the AxD
reaches. Larger AxDs tend to be more complex, non-spherical shapes (Pearson’s r: −0.7366, p < 0.0001). (f), Correlation between the AxD lifetime
and the maximum AxD volume in the APP-PS1 mouse. Larger AxDs tend to have longer lifetimes (Pearson’s r: 0.4974, p = 0.0071). (g), Comparison
between the axon type (EPB en passant bouton axons, TB terminal bouton axons) and the maximum volume that the AxD reaches in the APP-
PS1 mouse. The size of AxDs is not related to the type of axon in which they are formed (Mann–Whitney U: 163.0; p = 0.6339)
Fig. 4 Re-formation of AxDs. Dendrites and axons expressing GFP (green) in contact with Aβ plaques stained with Methoxy-XO4 (blue) in the supragranular
layers of the somatosensory cortex of the dE9 mouse (two-photon microscopy). (a-d), Maximum projection of images taken around an Aβ plaque (40
images, z = 1 μm) at different time points. The AxD (dys 4; arrow) is smaller on day 10 (b), and has disappeared on day 126 (d). Notice that the parental
axon on day 126 is shortened. (e-g), Maximum projection of images taken around another Aβ plaque (40 images, z = 1 μm) at different time points. The
AxD (dys 3; arrow) disappeared on day 10 (f) but the parental axon remains. A new large AxD is generated at the same point on day 133. The days shown
refer to the number of days after day 0 (when imaging began). Scale bar (in g): 25.9 μm in a-d and 19.5 in e-g
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(n = 28) —not taking into account those AxDs that
were present on the first and/or last day of imaging.
Moreover, we found a correlation (Pearson’s r: 0.4974,
p = 0.0071) between the AxD lifetime and the max-
imum volume that the AxD reaches, that is, larger
AxDs had longer lifetimes and vice versa (Fig. 3f ).
When AxD loss occurred, it happened in two ways:
1- Loss of the whole axon where the AxD was present
(Figs. 1d–i and 3, Table 1). In addition, around Aβ
plaques, both normal-looking axons and dystrophic
axons could disappear (see Fig. 1d–i). However, we
cannot rule out the possibility of the normal axon
being dystrophic at a segment close to an Aβ plaque
in another microscopic field.
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Dys 7 EPB >110 No No No 150 4.83 No
Dys 8 EPB >168 No No No 176 5.33 No
Dys 9 EPB >168 No No No 165 12.58 No




















Dys 1 EPB 110 Yes No No 778 20.2 Yes No
Dys 2 EPB 2a: 47
2b: >88





Dys 3 TB >63 Yes Yes No 514 24.49 Yes No
Dys 4 EPB 160 Yes Yes No 2814 20.14 Yes No
Dys 5 TB >138 No No No 565 14.77 Yes No
Dys 6 EPB 124 Yes Yes No 755 16.01 No No
Dys 7 TB 95 Yes Yes No 565 4.03 Yes No
Dys 8 TB 101 Yes Yes No 1496 27.46 Yes No
Dys 9 TB >47 Yes No No 512 21.30 No Yes
Dys 10 EPB 59 Yes Yes No 221 8.10 No No
Dys 11 EPB 51 Yes No No 64 5.00 No No
Dys 12 EPB 72 Yes Yes No 259 9.45 No No
Dys 13 TB >131 No No No 274 18.84 No Yes
Dys 14 EPB 14a: 29
14b: >40





Dys 15 EPB 15a: >23
15b: 117





Dys 16 TB 37 Yes Yes No 48 4.80 No No
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Fig. 5 Re-growing phenomenon in a dystrophic axon. (a-d), Maximum projection of a stack of images taken in the supragranular layers of the
somatosensory cortex of the APP-PS1 mouse at four different time points (two-photon microscopy). To facilitate the visualization of the axon of interest,
only those optical sections where this axon was present were used for the maximum projections (32 sections in a, 30 in b, 10 in c and 15 in d; z-step:
1 μm). Panels a-d correspond to the same regions and days as those also illustrated in Fig. 1d-g. In day 61 (c), the distal part of the axon (white arrowheads)
was lost just before the dystrophic part (dys 9, blue arrowhead in b). In day 68 (d), the axon starts to re-grow (red arrowheads). The inset in d shows the
growth cone. (e-h), Schematic representation from images a-d, respectively, showing the axon of interest (green) and the re-growth segment (red). (i, j),
Maximum projection of a stack of lower magnification images (89 sections in i and 98 in j; z-step: 0.7 μm), showing that the new axon segment (in d) can
re-grow (red arrowheads) longer distances over time (re-growth segment: 73.9 μm in i and 104.5 μm in j). The square delimits the size of the regions shown
in a-d. (k, l), Schematic representation from images i-j, respectively, showing the axon of interest (green) and the re-growth segment (red). Note that the
re-growth axonal segment has changed its trajectory whereas the original axon segment maintains the original trajectory. The days shown refer to the
number of days after day 0 (when imaging began). Scale bar (in l): 24 μm in a-h, 11.6 μm in d (inset) and 20.6 μm in i-l
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2- Loss of the dystrophic structures only, but not the
parental axon. Interestingly, in some of these cases,
after a variable period of time, new AxDs appeared
at the same point of the axon where the previous
AxD had been located. This re-formation
phenomenon of AxDs always occurred at the edge
of the axon (Figs. 3 and 4; Additional file 5; Table 1).
Electron microscopy Using correlative FIB/SEM, we
were able to analyze a region of approximately 1200 μm3
where an AxD had been observed in vivo to have disap-
peared (Fig. 6). In this region, at the ultrastructural level,
we found an activated microglial cell containing a large
amount of electron-dense material, full of phagocytosed
fragments of membranes and organelles. This accumula-
tion of electron-dense material corresponded to the
auto-fluorescence observed with the two-photon micro-
scope (Additional file 1) and maintained days later at a
point where an AxD was lost (Additional file 7). Further-
more, we used correlative two-photon in vivo imaging
and TEM of GFP-expressing AxD near to Aβ plaque.
We found that in some cases, microglial cells with nu-
merous phagocytic inclusions were in close apposition
to AxDs, suggesting that these cells are participating in
phagocytosis of AxDs (e.g., see [56]) (Fig. 7d).
Type of axon and dystrophic pathology
We were also interested in knowing if different types of
axons seem to be selectively vulnerable to the amyloid
pathology. We distinguished two main types of axons:
En Passant Bouton (EPB) axons and Terminal Bouton
(TB) axons. EPB axons had a high density of en passant
boutons and relatively few spine-like terminal boutons.
TB axons were similar to the EPB axons but had a high
density of spine-like terminal boutons. Moreover, we
could distinguish thin and thick EPB axons. In the dE9
mouse, 80% (8 out of 10) of the AxDs were present in
EPB axons (see Fig. 4e–g) and the remaining 20% (2 out
of 10) were in TB axons (see Fig. 2). In the APP-PS1
mouse, it was possible to analyze a larger number of AxDs
(n = 39) (see next section and Additional file 6). In this
case, 60% (24 out of 39) of the AxDs were present in EPB
axons —Fig. 1d–i; 1 out of these 24 AxDs was present in a
thick-EPB axon, see Fig. 8a, b— and the remaining 40%
(15 out of 39) were in TB axons (Additional file 4 a–i). In
addition, we calculated the number of EPB and TB axons
in our images (on day 0 of imaging) in the APP-PS1
mouse model and it was estimated to be 71 and 29%, re-
spectively. Thus, the presence of higher numbers of AxDs
in EPB axons could be explained by the higher numbers
of EPB axons. When we compared the maximum
AxD volume depending on the type of axon, we did
not observe significant differences between AxDs in
EPB axons (419.6 ± 138.5 μm3) and TB axons (374.3
± 100.4 μm3) (Mann–Whitney U: 163.0; p = 0.6339).
Thus, the size of AxDs was not related to the type of
axon in which they were formed (Fig. 3g).
In summary, our data suggest that AxDs were formed
in a quarter of GFP-expressing axons, which indicates a
selective vulnerability. AxDs, especially those reaching
larger sizes, had long lifetimes and appeared as highly
plastic structures with large variations in size and shape
and axonal sprouting over time. Moreover, they seemed
to be formed on different types of axons. Finally, it ap-
peared that microglial cells which are associated with
phagocytic activity, may contribute to the disappearance
and morphological changes of AxDs. These and other
results are summarized in Table 1.
Relationship between Aβ plaques and AxD formation and
development
In order to study early events regarding the formation of
AxDs and Aβ plaques, the APP-PS1 mouse was used
due to the early Aβ plaque development and high dens-
ity of Aβ plaques in the neocortex in this mouse com-
pared to the dE9 mouse. Using panoramic and high
resolution images (Additional file 6 a-f ), it was possible
to study 52 AxDs (5 of which were not associated with
Aβ plaques) and 33 Aβ plaques (Additional file 6), 15 of
which were pre-existing Aβ plaques (Aβ plaques that
were already present on the first day of imaging) and 18
were new Aβ plaques (Aβ plaques that appeared during
the imaging period).
– The vast majority of AxDs were associated with Aβ
plaques and in all these cases the formation of AxDs
was observed after the appearance of the Aβ plaques
(n = 18). However, in a small number of cases we
observed an axon with two AxDs (n = 5 out of 52);
one small AxD that was not associated with Aβ
plaques, and another which was close to an Aβ
plaque (Fig. 8e).
– There was a correlation (Spearman r: 0.6173, p < 0.0001)
between the maximum size of a given AxD and the
maximum size of the Aβ plaque with which it is
associated, in such a way that large AxDs were present
only around large Aβ plaques, whereas small Aβ plaques
were associated only with small AxDs. Nevertheless,
both large and small AxDs were present around large
Aβ plaques (Fig. 8a-d, h).
– There was a correlation (Spearman r: −0.4711,
p = 0.0022) between the maximum AxD volume
and the time of AxD appearance, such that
larger AxDs developed earlier than smaller
AxDs in the animal lifetime (Fig. 8a-d, g).
– When we studied the distribution of the 47 AxDs
associated with Aβ plaques over time, we observed
that most of them developed during the imaging
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Fig. 6 Correlative two-photon in vivo imaging and FIB/SEM microscopy. (a, b), Optical single plane images taken at two different time points at the
same region in layer I of the somatosensory cortex of the dE9 mouse, showing a Methoxy-X04-stained plaque (blue) and GFP-expressing processes.
There is a loss of an AxD (arrow) in the space of 1 week. (c), Same region as in a, b taken ex vivo after the perfusion of the animal on day 8. This image
was obtained by the combination of two optical single planes: one taken at the same z-level as in a, b and the other taken 4 μm above it, showing
the NIRB marks (pseudocolored in yellow and orange) performed to locate the region of interest at the ultrastructural level. (d), Electron-micrograph
picture from the last ultrathin section taken from the surface of the block that was further analyzed by FIB/SEM microscopy. The same NIRB marks
(pseudocolored in yellow and orange) as in c can be seen. The plaque halo is pseudocolored in green. The rectangle shows the position and the x, z
dimensions of the FIB/SEM stack that was obtained. The same rectangle is shown in a-c. The three dashed lines inside the rectangle show the perpendicular
plane in the approximate region where images e-g were obtained by FIB/SEM. (e-g), Examples of FIB/SEM images that were taken in the
z = 9.15 μm image stack (305 images of 30 nm thickness). Using Reconstruct software, the AxDs (green) and the microglial cell (red) that were present in
the stack of images were segmented every 2 sections. (i), 3D visualization of the segmented elements (microglial cell: red, AxDs: green). There is an activated
microglia cell in the region where the loss of a GFP-expressing AxD was observed. Scale bar (in g): 18.2 μm in a-c; 5.1 μm in d; 1.8 μm in e-h
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period —only 15% of them were present from the
first day of imaging (day 100). At the end of the
imaging period, around 70% of AxDs had been lost,
in most cases due to the disappearance of the whole
axon (76%) (Fig. 8f, Additional file 6 a-f ).
Discussion
In our study, we observed that around 22 and 28% of
the axons adjacent to Aβ plaques developed dystrophic
pathology in the dE9 and APP-PS1, respectively. This is
an interesting finding since it indicates that most of the
Fig. 7 Correlative two-photon microscopy and TEM of an Aβ plaque. (a), Maximum projection of images taken from a GFP-expressing AxD near
an Aβ plaque stained with Methoxy-X04 (blue) on day 162 (the same AxD (dys 7) as in Fig. 1a-c – red arrow). (b), Ex vivo single plane of the AxD (note
that some NIRB marks were made around the region of interest to locate it in subsequent processing steps; marks have been labeled with asterisks). (c),
Low-magnification electron micrograph showing the Aβ plaque (the central core formed by fibrillar Aβ peptide has been pseudocolored in blue). The
GFP-expressing AxD (dys 7) that was imaged in vivo is surrounded by the laser marks (pseudocolored in orange and labeled with asterisks). Rectangles
delimit the regions shown at a higher magnification in panels d, e. (d), Image showing a microglial cell with numerous phagocytic inclusions (arrows) in
close apposition to an AxD, suggesting that this cell is participating in phagocytosis of the AxD. Microglial cell was identified based on its ultrastructural
characteristics. (e), Higher magnification of dys 7. Note that autophagic vacuoles take up a large area of the AxD contents, and also that the AxD is
almost devoid of any normal-looking organelles. A normal-looking asymmetric synapse can be observed in close apposition to the AxD (arrowhead).
Scale bar (in e): 23.1 μm in a, b; 3 μm in c; 0.61 μm in d; 0.52 μm in e
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Fig. 8 Relationship between Aβ plaques and AxDs formation and development. (a, b), Maximum projection of images (120 images, z = 0.3 μm)
showing the presence of a large AxD (blue arrow) and a small AxD (red arrow) (GFP, green) close to a large plaque stained with Methoxy-X04
(blue) (b). Note that the larger AxD starts to develop around day 130 (animal age). (c, d), Maximum projection of images (120 images, z = 0.3 μm)
showing the presence of smaller AxDs (red arrows) (GFP, green) close to a small Aβ plaque stained with Methoxy-X04 (blue) (d). These two smaller
AxDs appear around day 232 (animal age). (c). Panoramic images that show the regions in panels a - d are in the Additional file 6. (e), Maximum
projection of images (134 images, z = 0.3 μm) showing GFP-expressing neurites and Aβ plaques stained with Methoxy-X04 (blue). There is an axon
with two AxDs: one small AxD that is not associated with Aβ plaques (arrowhead), and another which is close to an Aβ plaque stained with
Methoxy-X04 (arrow). The days shown refer to the animal age (the imaging began on day 100 of the animal lifetime). (f), Graph showing the
percentage of the total number of AxDs (n = 47) that are present over time. Days in X correspond to the bin center (bin width = 20 days). (g),
Correlation (Spearman r: −0.4711, p = 0.0022) between the maximum AxD volume and the day of AxD appearance, indicating that larger AxDs
develop earlier than smaller AxDs in the animal lifetime. (h), Correlation (Spearman r: 0.6173, p < 0.0001) between the maximum volume that an
AxD reaches and the maximum volume of the Aβ plaque it is associated with. Large AxDs are present only around large Aβ plaques. Scale bar
(in e): 25.1 μm in a-d; 28.4 μm in e
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axons near the Aβ plaques are resistant to this path-
ology. Thus, this raises the question as to why some
axons (a minority) seem to be more susceptible than
others to the dystrophic pathology.
Using the GFP-M model, it was possible to analyze
supragranular layers axons which have been reported
[16] to originate mainly from neurons whose soma are
located in cortical layers II/III/V (type A3 axon), layer
VI (type A2 axon) and thalamus (type A1 axon). These
axons are morphologically very similar to thin-EPB, TB
and thick-EPB axons, respectively, as defined in the
present study. In previous in vivo studies regarding bou-
ton turnover in axons present in layer I of the mouse
barrel cortex, it was found that axons from layer VI were
highly plastic, followed by axons from layer II/III/V that
showed intermediate levels of plasticity and thalamocor-
tical axons in which most of the boutons were persistent
[16]. In the present study, we found dystrophic path-
ology in all these types of axons. However, the majority
of axons in contact with Aβ plaques did not develop
AxDs. In this regard, it is important to take into account
that pyramidal neurons from different layers and even
those located in the same layer have different morpho-
logical, neurochemical and physiological properties (e.g.,
[54]). Thus, it is possible that particular types of neurons
located in layers II/III/V, layer VI and in the thalamus
are more susceptible to developing dystrophic pathology.
Indeed, previous studies mainly using a variety of neuro-
chemical markers showed that there are some subpopu-
lations of neurons selectively vulnerable to the AxD
development, e.g., those cortico-cortical fibers that ex-
press SMI-312 and GAP-43 [37], or neurofilament triplet
proteins (NF) [18, 44]. Furthermore, we analyzed only
the supragranular layers and it is possible that the suscep-
tibility of the axons in contact with Aβ plaques in layers
IV to VI is different to the observations in the present
study in the supragranular layers. Thus, further studies are
necessary to identify the subpopulation(s) of pyramidal
cells that are more susceptible to this pathology.
The relationship between the formation of extracellu-
lar Aβ deposits and their associated AxDs remains
elusive. For years it has been considered that the forma-
tion of AxDs was a consequence of Aβ deposits or
microglia activation, but not an active participant in the
pathogenesis of the Aβ plaques (see [20]). However, this
view is changing and there are increasing data sug-
gesting that beta-secretase 1 (BACE1) elevation and
associated Aβ overproduction occurs inside the AxDs
[26, 27, 46, 55, 64] (see Additional file 8). Moreover,
Aβ is a possible cause of the alterations in axonal trans-
port [50]. If a partial transport defect allows more time for
axonal APP processing as suggested [55], then this could
generate more Aβ, feeding back into a worsening trans-
port defect and progressive enlargement of both Aβ
plaques and AxDs. These facts —together with anomalous
mitochondrial function and oxidative stress, autophagy
and altered lysosomal processing considered in synthesis
with the mechanisms of disrupted axonal transport— sug-
gest that AxDs are an important source of extracellular
amyloid deposits (see [20]). The plaque induction of neur-
itic changes and the contribution of AxDs to Aβ depos-
ition are probably not mutually exclusive and could occur
concomitantly even in the same AxD.
Several authors have also contributed to the in vivo
study of AxDs, providing information about their forma-
tion near Aβ plaques and their probability of recovery
after different treatments [13, 15, 23, 53, 59]. However,
in these studies, the pathology was followed over rela-
tively short time periods (3 days to 5 weeks maximum)
and no detailed morphometric studies were performed.
Plasticity and axonal sprouting has been observed
around amyloid plaques performing in vitro and ex
vivo studies using different IHC markers (e.g., GAP-43)
([38, 40, 47, 49, 65] see [5] for a review). The existence
of many growth factors around the Aβ plaques has
been studied and sprouting has been proposed as a
compensatory mechanism for the synaptic alterations
that take place near Aβ plaques [39, 45, 63]. However,
this plasticity phenomenon had not been detailed de-
scribed and quantified in vivo to date. An important
advantage of our study was that the AxDs were
followed over long periods of time (up to 210 days). A
great number of axonal segments were followed and
AxDs were studied individually to further analyze the
heterogeneous changes between different AxDs and in
the same AxD over time (plasticity of AxDs). The individ-
ual study of the axons and their dystrophies was possible
by means of the GFP-M transgenic model that has a low
density of neurons expressing GFP. Moreover, the use of
specialized tools allowed the performance of 3D recon-
struction and measurement of volumes to carry out a de-
tailed quantitative study. Most AxDs were formed and
developed during the imaging period, and numerous
AxDs had already disappeared by the end of this period
(Additional file 9). We were able to observe that AxDs
had long lifetimes (commonly more than 100 days). In the
APP-PS1 mouse, amyloid pathology and related dys-
trophic neuritic changes around the Aβ plaques developed
earlier than in the dE9 mouse (Aβ plaque deposition in
the neocortex begins around the age of 6 months in the
dE9 [30] and 2 months in the APP-PS1 mouse [48]). How-
ever, we observed in both models similar findings regard-
ing the high AxD plasticity over time. The most important
observations are the following: i) AxDs did not grow
steadily —their volume increased and decreased over
time, showing dramatic volume differences at distinct time
points; ii) AxDs located at the end of the axon could also
become fully reversed while the parental axon remained
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and a new AxD could be generated after a variable period
of time; iii) Axonal sprouting was a common event: prom-
inent morphological changes occurred in larger AxDs over
time and interestingly the re-growth of long axonal seg-
ments from axons that were cut at a dystrophic point was
observed in the APP-PS1 mouse. This is interesting since
it has been recently observed in vivo that, depending on
the cell type, some ablated axons spontaneously re-grow
and although they never reconnect to their original
targets, axons consistently form new boutons at compar-
able pre-lesion synaptic densities, implying the existence
of intrinsic homeostatic programs, which regulate synaptic
numbers on regenerating axons [14]. We cannot rule out
the possibility that the absence of this phenomenon in
dE9 could suggest that the sample size was not sufficient,
or an intrinsic difference of the amyloid pathology be-
tween the two mouse lines.
Taking these results together, the existence of this
neuronal plasticity (especially around Aβ plaques) in-
creases the likelihood that the synaptic abnormalities
associated with the Aβ plaques can be reversed within a
certain time window before most AxDs and their axons
have disappeared. Thus, this opens up the possibility
that early prevention or elimination of the Aβ plaques
with appropriate therapeutic strategies might prevent
disease progression and promote functional axon regen-
eration and the recovery of neural circuits.
Conclusion
AxDs were formed only in a quarter of GFP-expressing
axons near Aβ-plaques, which indicates a selective vulner-
ability. AxDs, especially those reaching larger sizes, had
long lifetimes and appeared as highly plastic structures
with large variations in size and shape and axonal sprout-
ing over time. We observed that most AxDs were formed
and developed during the imaging period, and numerous
AxDs had already disappeared by the end of this time.
This work is the first in vivo study analyzing quantitatively
the high plasticity of the axonal pathology around Aβ pla-
ques. We hypothesized that a therapeutically early preven-
tion of Aβ plaque formation or their growth might halt
disease progression and promote functional axon regener-
ation and the recovery of neural circuits.
Additional files
Additional file 1: Figure S1. Location of auto-fluorescent spots.
(PDF 371 kb)
Additional file 2: Table S1. Table showing the number of imaging
positions that was successfully imaged weekly during near 6 months.
(PDF 260 kb)
Additional file 3: Figure S2. Correlative light and FIB/SEM microscopy.
(PDF 317 kb)
Additional file 4: Figure S3. Size ratio of dystrophic segments.
(PDF 393 kb)
Additional file 5: Figure S4. Re-formation of AxDs and sprouting
phenomenon (re-growth) in the APP-PS1 mouse. (PDF 341 kb)
Additional file 6: Figure S5. Relationship between Aβ plaques and
AxDs formation and development. Quantitative analysis of different types
of Aβ plaques. (PDF 463 kb)
Additional file 7: Figure S6. Behavior of auto-fluorescent spots after
the elimination of an AxD. (PDF 204 kb)
Additional file 8: Figure S7. Quantitative study of the neurochemical
characteristics of the AxDs. (PDF 351 kb)
Additional file 9: Figure S8. Schematic representation of Aβ plaques
and AxDs development over time. (PDF 200 kb)
Abbreviations
3D: Three-dimensional; AD: Alzheimer’s disease; APP-PS1: Amyloid Precursor
Protein – Preseniline 1; AxDs: Axonal dystrophies; Aβ: Amyloid β;
BP: Bandpass; EPB: En Passant Bouton axons; FIB/SEM: Focused ion beam/
scanning electron microscopy; GFP-M: Green fluorescent protein – M;
NFTs: Neurofibrillary tangles; NIRB: Near infrared branding; SP: Short pass;
TB: Terminal Bouton axons; TEM: Transmission electron microscopy
Acknowledgment
We would like to thank Matthias Jucker who kindly provided the APP-PS1
mice used in this study.
Funding
The work was supported by grants from the Spanish Ministry of Economy and
Competitiveness (MINECO) (BFU2012-34963 to JF), the Centre for Networked
Biomedical Research on Neurodegenerative Diseases (CIBERNED, CB06/05/0066)
(to JF), a grant from the Alzheimer’s Association (ZEN-15-321663) (to JF) and the
Humboldt Research Fellowship for Postdoctoral Researchers (LBL).
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
LBL: Conception or design of the work, Data collection, Data analysis and
interpretation, Drafting the article, Critical revision of the article, Final approval
of the version to be published. SVF: Data collection, Data analysis and
interpretation, Critical revision of the article. EFR: Data collection, Data analysis
and interpretation, Critical revision of the article. AMP: Data collection, Data
analysis and interpretation, Critical revision of the article. JRR: Data collection,
Data analysis and interpretation, Critical revision of the article. MMD: Critical
revision of the article. JF: Critical revision of the article, Final approval of the
version to be published. JH: Critical revision of the article, Final approval of the
version to be published. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1German Center for Neurodegenerative Diseases-Munich site (DZNE-M) and
Center for Neuropathology and Prion Research (ZNP), Ludwig-Maximilians
University, Munich, Feodor-Lynen-St 23, 81377 Munich, Germany.
2Laboratorio Cajal de Circuitos Corticales, Centro de Tecnología Biomédica,
Universidad Politécnica de Madrid, Madrid, Spain. 3Departamento de
Arquitectura y Tecnología de Sistemas Informáticos, Escuela Técnica Superior
de Ingenieros Informáticos, Universidad Politécnica de Madrid, Madrid, Spain.
4Instituto Cajal, Consejo Superior de Investigaciones Científicas, Madrid,
Spain. 5Centro de Investigación Biomédica en Red sobre Enfermedades
Neurodegenerativas (CIBERNED), ISCIII, Madrid, Spain. 6Munich Cluster of
Blazquez-Llorca et al. Acta Neuropathologica Communications  (2017) 5:14 Page 16 of 18
Systems Neurology (SyNergy), Ludwig-Maximilians University, Munich,
Germany. 7Departmento de Psicobiología, Facultad de Psicología,
Universidad Nacional de Educación a Distancia (UNED), C/Juan del Rosal 10,
28040 Madrid, Spain.
Received: 12 December 2016 Accepted: 26 January 2017
References
1. Alzheimer A (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine
Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64:146–148
2. Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA,
Kerschensteiner M, Misgeld T, Coleman MP (2009) Severely dystrophic
axons at amyloid plaques remain continuous and connected to viable
cell bodies. Brain J Neurol 132:402–416
3. Alpar A, Ueberham U, Bruckner MK, Seeger G, Arendt T, Gartner U (2006)
Different dendrite and dendritic spine alterations in basal and apical arbors
in mutant human amyloid precursor protein transgenic mice. Brain Res
1099:189–198
4. Alpar A, Ueberham U, Seeger G, Arendt T, Gartner U (2007) Effects of wild-
type and mutant human amyloid precursor protein on cortical afferent
network. Neuroreport 18:1247–1250
5. Arendt T (2001) Alzheimer’s disease as a disorder of mechanisms underlying
structural brain self-organization. Neuroscience 102:723–765
6. Arendt T (2009) Synaptic degeneration in Alzheimer’s disease. Acta
Neuropathol 118:167–179
7. Bishop D, Nikic I, Brinkoetter M, Knecht S, Potz S, Kerschensteiner M, Misgeld
T (2011) Near-infrared branding efficiently correlates light and electron
microscopy. Nat Methods 8:568–570
8. Bittner T, Burgold S, Dorostkar MM, Fuhrmann M, Wegenast-Braun BM,
Schmidt B, Kretzschmar H, Herms J (2012) Amyloid plaque formation
precedes dendritic spine loss. Acta Neuropathol 124:797–807
9. Bittner T, Fuhrmann M, Burgold S, Ochs SM, Hoffmann N, Mitteregger G,
Kretzschmar H, LaFerla FM, Herms J (2010) Multiple events lead to dendritic
spine loss in triple transgenic Alzheimer’s disease mice. PLoS One 5:e15477
10. Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton
T, Jedidi I, Gohin M, Wirths O et al (2003) Time sequence of maturation of
dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic
mice. Exp Neurol 184:247–263
11. Blazquez-Llorca L, Hummel E, Zimmerman H, Zou C, Burgold S, Rietdorf J,
Herms J (2015) Correlation of two-photon in vivo imaging and FIB/SEM
microscopy. J Microsc 259:129–136
12. Braak H, Thal DR, Ghebremedhin E, Del Tredici K (2011) Stages of the
pathologic process in Alzheimer disease: age categories from 1 to 100
years. J Neuropathol Exp Neurol 70:960–969
13. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis
CA, Bales KR, Paul SM, Hyman BT et al (2005) Anti-Abeta antibody treatment
promotes the rapid recovery of amyloid-associated neuritic dystrophy in
PDAPP transgenic mice. J Clin Invest 115:428–433
14. Canty AJ, Huang L, Jackson JS, Little GE, Knott G, Maco B, De Paola V (2013)
In-vivo single neuron axotomy triggers axon regeneration to restore
synaptic density in specific cortical circuits. Nat Commun 4:2038
15. D’Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT (2003)
In vivo multiphoton imaging of a transgenic mouse model of Alzheimer
disease reveals marked thioflavine-S-associated alterations in neurite
trajectories. J Neuropathol Exp Neurol 62:137–145
16. De Paola V, Holtmaat A, Knott G, Song S, Wilbrecht L, Caroni P, Svoboda K
(2006) Cell type-specific structural plasticity of axonal branches and boutons
in the adult neocortex. Neuron 49:861–875
17. DeFelipe J, Fairen A (1993) A simple and reliable method for correlative
light and electron microscopic studies. J Histochem Cytochem 41:769–772
18. Dickson TC, King CE, McCormack GH, Vickers JC (1999) Neurochemical
diversity of dystrophic neurites in the early and late stages of Alzheimer’s
disease. Exp Neurol 156:100–110
19. Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M,
Nerbonne JM, Lichtman JW, Sanes JR (2000) Imaging neuronal subsets in
transgenic mice expressing multiple spectral variants of GFP. Neuron 28:41–51
20. Fiala JC (2007) Mechanisms of amyloid plaque pathogenesis. Acta
Neuropathol 114:551–571
21. Fiala JC (2005) Reconstruct: a free editor for serial section microscopy.
J Microsc 218:52–61
22. Fuhrmann M, Mitteregger G, Kretzschmar H, Herms J (2007) Dendritic
pathology in prion disease starts at the synaptic spine. J Neurosci Off J Soc
Neurosci 27:6224–6233
23. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin
labels amyloid pathology in vivo, disrupts existing plaques, and partially restores
distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095–1104
24. Geddes JW, Anderson KJ, Cotman CW (1986) Senile plaques as aberrant
sprout-stimulating structures. Exp Neurol 94:767–776
25. Geddes JW, Monaghan DT, Cotman CW, Lott IT, Kim RC, Chui HC (1985) Plasticity
of hippocampal circuitry in Alzheimer’s disease. Science 230:1179–1181
26. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E (2010)
Intraneuronal beta-amyloid accumulation and synapse pathology in
Alzheimer’s disease. Acta Neuropathol 119:523–541
27. Gouras GK, Willen K, Faideau M (2014) The inside-out amyloid hypothesis and
synapse pathology in Alzheimer’s disease. Neurodegener Dis 13:142–146
28. Grutzendler J, Helmin K, Tsai J, Gan WB (2007) Various dendritic
abnormalities are associated with fibrillar amyloid deposits in Alzheimer’s
disease. Ann N Y Acad Sci 1097:30–39
29. Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. Comparative
cytoarchitectonic atlas of the C57Bl/6 and 129/SV mouse brains. 2000.
Elsevier, New York City
30. Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR
(2004) APP processing and amyloid deposition in mice haplo-insufficient for
presenilin 1. Neurobiol Aging 25:885–892
31. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP,
Debnath ML, Holt DP, Wang Y, Hyman BT (2002) Imaging Abeta plaques in
living transgenic mice with multiphoton microscopy and methoxy-X04, a
systemically administered Congo red derivative. J Neuropathol Exp Neurol
61:797–805
32. Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-
Espinosa I, Ferrer I, DeFelipe J (2009) Widespread changes in dendritic
spines in a model of Alzheimer’s disease. Cereb Cortex 19:586–592
33. Knafo S, Venero C, Merino-Serrais P, Fernaud-Espinosa I, Gonzalez-Soriano J,
Ferrer I, Santpere G, DeFelipe J (2009) Morphological alterations to neurons
of the amygdala and impaired fear conditioning in a transgenic mouse
model of Alzheimer’s disease. J Pathol 219:41–51
34. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-
Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM et al (2009) Oligomeric
amyloid beta associates with postsynaptic densities and correlates with
excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106:
4012–4017
35. Luebke JI, Weaver CM, Rocher AB, Rodriguez A, Crimins JL, Dickstein DL,
Wearne SL, Hof PR (2010) Dendritic vulnerability in neurodegenerative
disease: insights from analyses of cortical pyramidal neurons in transgenic
mouse models. Brain Struct Funct 214:181–199
36. Masliah E, Alford M, Adame A, Rockenstein E, Galasko D, Salmon D, Hansen
LA, Thal LJ (2003) Abeta1-42 promotes cholinergic sprouting in patients
with AD and Lewy body variant of AD. Neurology 61:206–211
37. Masliah E, Mallory M, Deerinck T, DeTeresa R, Lamont S, Miller A, Terry RD,
Carragher B, Ellisman M (1993) Re-evaluation of the structural organization of
neuritic plaques in Alzheimer’s disease. J Neuropathol Exp Neurol 52:619–632
38. Masliah E, Mallory M, Hansen L, Alford M, Albright T, DeTeresa R, Terry R,
Baudier J, Saitoh T (1991) Patterns of aberrant sprouting in Alzheimer’s
disease. Neuron 6:729–739
39. Masliah E, Xie F, Dayan S, Rockenstein E, Mante M, Adame A, Patrick CM,
Chan AF, Zheng B (2010) Genetic deletion of Nogo/Rtn4 ameliorates
behavioral and neuropathological outcomes in amyloid precursor protein
transgenic mice. Neuroscience 169:488–494
40. McKinney RA, Debanne D, Gahwiler BH, Thompson SM (1997) Lesion-
induced axonal sprouting and hyperexcitability in the hippocampus in vitro:
implications for the genesis of posttraumatic epilepsy. Nat Med 3:990–996
41. Merchan-Perez A, Rodriguez JR, Alonso-Nanclares L, Schertel A, Defelipe
J (2009) Counting synapses using FIB/SEM microscopy: a true revolution for
ultrastructural volume reconstruction. Front Neuroanat 3:18
42. Merino-Serrais P, Benavides-Piccione R, Blazquez-Llorca L, Kastanauskaite A,
Rabano A, Avila J, DeFelipe J (2013) The influence of phospho-tau on
dendritic spines of cortical pyramidal neurons in patients with Alzheimer’s
disease. Brain J Neurol 136:1913–1928
43. Merino-Serrais P, Knafo S, Alonso-Nanclares L, Fernaud-Espinosa I, DeFelipe J
(2011) Layer-specific alterations to CA1 dendritic spines in a mouse model
of Alzheimer’s disease. Hippocampus 21:1037–1044
Blazquez-Llorca et al. Acta Neuropathologica Communications  (2017) 5:14 Page 17 of 18
44. Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC (2013) Neurites containing the
neurofilament-triplet proteins are selectively vulnerable to cytoskeletal pathology
in Alzheimer’s disease and transgenic mouse models. Front Neuroanat 7:30
45. Nelson AR, Kolasa K, McMahon LL (2014) Noradrenergic sympathetic
sprouting and cholinergic reinnervation maintains non-amyloidogenic
processing of AbetaPP. J Alzheimers Dis 38:867–879
46. Nixon RA (2006) Autophagy in neurodegenerative disease: friend, foe or
turncoat? Trends Neurosci 29:528–535
47. Phinney AL, Deller T, Stalder M, Calhoun ME, Frotscher M, Sommer B,
Staufenbiel M, Jucker M (1999) Cerebral amyloid induces aberrant axonal
sprouting and ectopic terminal formation in amyloid precursor protein
transgenic mice. J Neurosci Off J Soc Neurosci 19:8552–8559
48. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L,
Calhoun ME, Jaggi F, Wolburg H, Gengler S et al (2006) Abeta42-driven
cerebral amyloidosis in transgenic mice reveals early and robust pathology.
EMBO Rep 7:940–946
49. Roisen FJ, Bartfeld H, Nagele R, Yorke G (1981) Ganglioside stimulation of
axonal sprouting in vitro. Science 214:577–578
50. Rui Y, Tiwari P, Xie Z, Zheng JQ (2006) Acute impairment of mitochondrial
trafficking by beta-amyloid peptides in hippocampal neurons. J Neurosci Off
J Soc Neurosci 26:10480–10487
51. Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-
Vargas D, Moreno-Gonzalez I, De Castro V, Jimenez S, Ruano D, Vizuete M et
al (2012) Abnormal accumulation of autophagic vesicles correlates with
axonal and synaptic pathology in young Alzheimer’s mice hippocampus.
Acta Neuropathol 123:53–70
52. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, Jones PB, Stern EA, Bacskai
BJ, Hyman BT (2007) Impaired spine stability underlies plaque-related spine
loss in an Alzheimer’s disease mouse model. Am J Pathol 171:1304–1311
53. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT,
Bacskai BJ, Hyman BT (2005) Dendritic spine abnormalities in amyloid
precursor protein transgenic mice demonstrated by gene transfer and
intravital multiphoton microscopy. J Neurosci OffJ Soc Neurosci 25:7278–7287
54. Spruston N (2008) Pyramidal neurons: dendritic structure and synaptic
integration. Nat Rev Neurosci 9:206–221
55. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R,
Davies P, Masliah E, Williams DS et al (2005) Axonopathy and transport deficits
early in the pathogenesis of Alzheimer’s disease. Science 307:1282–1288
56. Streit WJ, Kreutzberg GW (1988) Response of endogenous glial cells to motor
neuron degeneration induced by toxic ricin. J Comp Neurol 268:248–263
57. Su JH, Cummings BJ, Cotman CW (1993) Identification and distribution of
axonal dystrophic neurites in Alzheimer’s disease. Brain Res 625:228–237
58. Su JH, Cummings BJ, Cotman CW (1998) Plaque biogenesis in brain aging
and Alzheimer’s disease. II. Progressive transformation and developmental
sequence of dystrophic neurites. Acta Neuropathol 96:463–471
59. Tsai J, Grutzendler J, Duff K, Gan WB (2004) Fibrillar amyloid deposition
leads to local synaptic abnormalities and breakage of neuronal branches.
Nat Neurosci 7:1181–1183
60. Vickers JC, Chin D, Edwards AM, Sampson V, Harper C, Morrison J (1996)
Dystrophic neurite formation associated with age-related beta amyloid
deposition in the neocortex: clues to the genesis of neurofibrillary
pathology. Exp Neurol 141:1–11
61. Vickers JC, King AE, Woodhouse A, Kirkcaldie MT, Staal JA, McCormack GH,
Blizzard CA, Musgrove RE, Mitew S, Liu Y et al (2009) Axonopathy and
cytoskeletal disruption in degenerative diseases of the central nervous
system. Brain Res Bull 80:217–223
62. Woodhouse A, Vickers JC, Adlard PA, Dickson TC (2009) Dystrophic neurites
in TgCRND8 and Tg2576 mice mimic human pathological brain aging.
Neurobiol Aging 30:864–874
63. Zhan SS, Kamphorst W, Van Nostrand WE, Eikelenboom P (1995)
Distribution of neuronal growth-promoting factors and cytoskeletal proteins
in altered neurites in Alzheimer’s disease and non-demented elderly. Acta
Neuropathol 89:356–362
64. Zhang XM, Cai Y, Xiong K, Cai H, Luo XG, Feng JC, Clough RW, Struble RG, Patrylo PR,
Yan XX (2009) Beta-secretase-1 elevation in transgenic mouse models of Alzheimer’s
disease is associated with synaptic/axonal pathology and amyloidogenesis:
implications for neuritic plaque development. Eur J Neurosci 30:2271–2283
65. Zhang XM, Xiong K, Cai Y, Cai H, Luo XG, Feng JC, Clough RW, Patrylo PR,
Struble RG, Yan XX (2010) Functional deprivation promotes amyloid plaque
pathogenesis in Tg2576 mouse olfactory bulb and piriform cortex.
Eur J Neurosci 31:710–721
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Blazquez-Llorca et al. Acta Neuropathologica Communications  (2017) 5:14 Page 18 of 18
